Prostate cancer patients already fighting to regain their health are today caught in the latest skirmish over the cost of treatment.
A bid to use the drug Abiraterone before chemotherapy has been rejected by officials at the National Institute for Health and Care (Nice), the drug approval body for the NHS.
At almost £3,000 per patient per month Nice says the benefits don't justify the price.
The decision has triggered a row which shakes at the foundations of how the value of drugs is measured.
The drug company Janssen is questioning how the organisation reached their decision.
It is looking like this system is coming apart at the seams. In their statement Health officials at Nice told me they have misgivings about the company's clinical results.
Today's decision comes just a week after a breast cancer drug was rejected on cost grounds.
In the increasingly complex junction between public health and private drugs - the idea that we cannot put a price on health looks ever more fanciful.